Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21258087 | 0.84 | AAK1 (0.36) | AAK1MMP13BUB1CA1CA2 | |
| SCHEMBL17618251 | 0.84 | AAK1 (0.36) | AAK1MMP13BUB1CA1CA2 | |
| SCHEMBL4145893 | 0.83 | AAK1 (0.37) | AAK1MMP13CA1CA2CA7 | |
| SCHEMBL23986814 | 0.82 | POLB (0.36) | AAK1MMP13BUB1CA1CA2 | |
| SCHEMBL23976692 | 0.82 | POLB (0.36) | AAK1MMP13BUB1CA1CA2 | |
| SCHEMBL8386740 | 0.79 | AAK1 (0.35) | AAK1MMP13CA1CA2CA7 | |
| SCHEMBL13731788 | 0.79 | AAK1 (0.35) | AAK1MMP13CA1CA2CA7 | |
| SCHEMBL9455522 | 0.79 | CA14 (0.41) | AAK1MMP13CA1CA2CA7 | |
| SCHEMBL7021061 | 0.79 | CA14 (0.41) | AAK1MMP13CA1CA2CA7 | |
| SCHEMBL18796420 | 0.79 | CA14 (0.41) | AAK1MMP13CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453048-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-9453048-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150225452-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-13 | — | — | US | disclosed |
| US-20150225452-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225452-A1 | IAP ANTAGONISTS | XIAP, API5, BIRC5 | AAK1 807/4885MMP13 2831/4885HIF1A 1865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.